Phio Pharmaceuticals
PHIO
11 hedge funds and large institutions have $117K invested in Phio Pharmaceuticals in 2024 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 3 increasing their positions, 0 reducing their positions, and 3 closing their positions.
67% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 3
10% more funds holding
Funds holding: 10 → 11 (+1)
0.42% less ownership
Funds ownership: 0.82% → 0.41% (-0.42%)
8% less capital invested
Capital invested by funds: $127K → $117K (-$9.86K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
+$20.4K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$15.8K |
| 3 |
TSS
Two Sigma Securities
New York
|
+$9.05K |
| 4 |
Cetera Investment Advisers
Schaumburg,
Illinois
|
+$3.63K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$791 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VF
Virtu Financial
New York
|
-$21K |
| 2 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$17.1K |
| 3 |
Wells Fargo
San Francisco,
California
|
-$13 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Cetera Investment Advisers
Schaumburg,
Illinois
| $24.5K | +$3.63K | +555 | +16% |
|
|
2
Geode Capital Management
Boston,
Massachusetts
| $19.7K | +$20.4K | +3,126 | New |
|
3
Vanguard Group
Malvern,
Pennsylvania
| $16.9K | – | – | – |
|
|
BCM
4
Bridgeway Capital Management
Houston,
Texas
| $16.4K | – | – | – |
|
|
5
Citadel Advisors
Miami,
Florida
| $15.2K | +$15.8K | +2,410 | New |
|
6
Cambridge Investment Research Advisors
Fairfield,
Iowa
| $10K | – | – | – |
|
|
TSS
7
Two Sigma Securities
New York
| $8.62K | +$9.05K | +1,384 | New |
|
|
TRCT
8
Tower Research Capital (TRC)
New York
| $3.97K | +$26 | +4 | +0.6% |
|
|
9
UBS Group
Zurich,
Switzerland
| $1.69K | +$791 | +121 | +80% |
|
|
AWM
10
Activest Wealth Management
Aventure,
Florida
| $57 | +$59 | +9 | New |
|
11
Bank of America
Charlotte,
North Carolina
| $26 | +$26 | +4 | New |
|
12
BlackRock
New York
| $1 | – | – | – |
|
|
VF
13
Virtu Financial
New York
| – | -$21K | -3,435 | Closed |
|
|
14
Bank of Montreal
Toronto,
Ontario, Canada
| – | -$17.1K | -2,222 | Closed |
|
|
15
Wells Fargo
San Francisco,
California
| – | -$13 | -2 | Closed |
|
PHIO Hedge Fund Activity: Q2 2024 in Review
11 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Phio Pharmaceuticals (PHIO) for Q2 2024, worth a combined $117K — down 7.8% from $127K a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new PHIO positions and 3 closed out — a net gain of 2 holders — while 3 added to existing stakes and 0 trimmed.
The largest buyer was Geode Capital Management, opening a new position worth an estimated $20.4K. The largest seller was Virtu Financial, exiting entirely with an estimated $21K sold.
- 11 institutional investors held Phio Pharmaceuticals (PHIO) as of Q2 2024, up from 10 in Q1 2024.
- Funds reported $117K of Phio Pharmaceuticals stock for Q2 2024, down 7.8% quarter-over-quarter.
- 5 funds opened new Phio Pharmaceuticals positions in Q2 2024 and 3 closed out, a net change of +2 holders.
- The largest Phio Pharmaceuticals buyer in Q2 2024 was Geode Capital Management, an estimated $20.4K added.
- The largest Phio Pharmaceuticals seller in Q2 2024 was Virtu Financial, an estimated $21K sold.
Based on aggregated 13F filings for Q2 2024.